Insight

David R. Liu: The first prime editing clinical trial has been cleared by U.S. FDA to begin

Photo of David R. Liu/X

May 1, 2024, 12:17

David R. Liu: The first prime editing clinical trial has been cleared by U.S. FDA to begin

David R. Liu, Core Institute Member and Vice-Chair of the Faculty at Broad Institute of MIT and Harvard, shared a post by Prime Medicine on X/Twitter:

“The first prime editing clinical trial has been cleared by U.S. FDA to begin: prime editing of HSCs to treat chronic granulomatous disease (CGD). Congratulations to Prime Medicine on achieving this key milestone only 4.5 years after we published the first prime editing paper.”

Quoting Prime Medicine’s post:

“We are pleased to announce that FDA has cleared our IND application for PM359 for the treatment of chronic granulomatous disease (CGD), enabling Prime to initiate its Phase 1/2 clinical trial in the US. Details.”

Source: David R. Liu/X and Prime Medicine/X

Broad Institute of MIT and Harvard cancer chronic granulomatous disease clinical trial David R. Liu FDA IND application OncoDaily Oncology PM359 Prime Medicine

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage